Trial site
Metabolic Research Institute, Inc
West Palm Beach, Florida 33401', United StatesNot linked to an institution yet
- 10running trials
- 13closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 317 trials
- Phase 25 trials
- Phase 41 trial
- Status
- Completed12 trials
- Active, not recruiting6 trials
- Recruiting4 trials
- Suspended1 trial
- Terminated1 trial
- Lead sponsor
- Eli Lilly and Company7 trials
- Novo Nordisk A/S6 trials
- Bayer2 trials
- Anji Pharma1 trial
- Aventusoft, LLC.1 trial
- and 7 more
Running trials
Recruiting
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
NCT07817251· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· Phase 3· Eli Lilly and Company· Source
Contact: Barry Horowitz, MD (principal investigator)
Active, not recruiting
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
NCT06334133· Phase 3· vTv Therapeutics· Source
Recruiting
PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG
NCT06567795· Aventusoft, LLC.· Source
Contact: Alayzah Garcia, BA
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471· Phase 3· Incyte Corporation· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Terminated
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
NCT06493578· Phase 2· Vyne Therapeutics Inc.· Source
Completed
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
NCT05901831· Phase 3· Bayer· Source
Completed
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
NCT06045221· Phase 3· Eli Lilly and Company· Source
Completed
Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia
NCT05889156· Phase 2· NorthSea Therapeutics B.V.· Source
Completed
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
NCT05823948· Phase 3· Novo Nordisk A/S· Source
Completed
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421· Phase 3· Eli Lilly and Company· Source
Completed
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
NCT05623189· Phase 2· HighTide Therapeutics (Hong Kong) Limited· Source
Completed
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
NCT05564039· Phase 4· Eli Lilly and Company· Source
Completed
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
NCT05254002· Phase 2· Bayer· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
NCT05352815· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
NCT05259033· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
NCT05013229· Phase 3· Novo Nordisk A/S· Source
Completed
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224
NCT04932512· Phase 2· Ionis Pharmaceuticals, Inc.· Source
Report an error